肾素-血管紧张素系统抑制与代偿期肝硬化肝脏相关事件及死亡率的关联
这项基于Optum数据库的国家队列研究纳入2009至2019年间4214例肝硬化成人,比较使用ACE抑制剂或ARB者与使用选择性β受体阻滞剂者的肝脏相关事件风险。结果显示ACE抑制剂/ARB使用者5年累积发生率较低(30.6% vs 41.3%),风险比aHR为0.69,并呈剂量反应关系;作者认为结果支持开展随机临床试验确认临床获益。
要点
- 在代偿期肝硬化成人中,ACE抑制剂/ARB使用与肝脏相关事件风险较低相关(aHR 0.69)。
- ACE抑制剂/ARB使用者5年累积发生率为30.6%,低于选择性β受体阻滞剂使用者的41.3%。
- ACE抑制剂/ARB处方≥1个限定日剂量时风险降低更明显(aHR 0.65),<1个限定日剂量时为aHR 0.87。
核心结论
- 在这项国家队列研究中,ACE抑制剂/ARB使用与代偿期肝硬化患者肝脏相关事件风险显著较低相关。
- 这些结果为开展随机临床试验以确认临床获益提供了支持。
研究设计与样本
- 国家队列研究,使用Optum数据库,纳入2009至2019年间肝硬化患者。
- 共纳入4214例肝硬化成人,其中ACE抑制剂/ARB使用者3155例,选择性β受体阻滞剂使用者1059例。
- 采用逆概率治疗加权计算累积发生率、绝对风险差异和Cox比例风险比。
主要发现
- 在逆概率治疗加权分析中,ACE抑制剂/ARB使用者(对比选择性β受体阻滞剂使用者)5年累积发生率为30.6%(95%CI 27.8%至33.2%) vs 41.3%(95%CI 34.0%至47.7%),绝对风险差异为-10.7%(95%CI -18.1%至-3.6%)。
- ACE抑制剂/ARB使用(对比选择性β受体阻滞剂使用)与肝脏相关事件风险较低相关(aHR 0.69;95%CI 0.60至0.80)。
- 存在剂量反应关系:对比选择性β受体阻滞剂使用,ACE抑制剂/ARB处方≥1个限定日剂量时aHR为0.65(95%CI 0.56至0.76),<1个限定日剂量时aHR为0.87(95%CI 0.71至1.07)。
- 结果在敏感性分析中稳健,例如比较ACE抑制剂/ARB使用者与非使用者以及按治疗分析。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: While renin-angiotensin system inhibition lowers the hepatic venous gradient, the effect on more clinically meaningful endpoints is less studied. We aimed to quantify the relationship between renin-angiotensin system inhibition and liver-related events (LREs) among adults with compensated cirrhosis. METHODS: In this national cohort study using the Optum database, we quantified the association between angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) use and LREs (hepatocellular carcinoma, liver transplantation, ascites, hepatic encephalopathy, or variceal bleeding) among patients with cirrhosis between 2009 and 2019. Selective beta-blocker (SBB) users served as the comparator group. We used demographic and clinical features to calculate inverse-probability treatment weighting-weighted cumulative incidences, absolute risk differences, and Cox proportional hazard ratios. RESULTS: Among 4214 adults with cirrhosis, 3155 were ACE inhibitor/ARB users and 1059 were SBB users. In inverse probability treatment weighting-weighted analyses, ACE inhibitor/ARB (vs SBB) users had lower 5-year cumulative incidence (30.6% [95% confidence interval (CI), 27.8% to 33.2%] vs 41.3% [95% CI, 34.0% to 47.7%]; absolute risk difference, -10.7% [95% CI, -18.1% to -3.6%]) and lower risk of LREs (adjusted hazard ratio [aHR], 0.69; 95% CI, 0.60 to 0.80). There was a dose-response relationship: compared with SBB use, ACE inhibitor/ARB prescriptions ≥1 defined daily dose (aHR, 0.65; 95% CI, 0.56 to 0.76) were associated with a greater risk reduction compared with <1 defined daily dose (aHR, 0.87; 95% CI, 0.71 to 1.07). Results were robust across sensitivity analyses such as comparing ACE inhibitor/ARB users with nonusers and as-treated analysis. CONCLUSIONS: In this national cohort study, ACE inhibitor/ARB use was associated with significantly lower risk of LREs in patients with compensated cirrhosis. These results provide support for a randomized clinical trial to confirm clinical benefit.
引用
- Elhence H, Dodge JL, Lee BP, et al. Association of Renin-Angiotensin System Inhibition With Liver-Related Events and Mortality in Compensated Cirrhosis. Clin Gastroenterol Hepatol. 2023. PMID: 37495200. doi:10.1016/j.cgh.2023.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。